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ABSTRACT  
Objectives: The main purpose of the study is to assess the causality, severity, preventability of ADRs and factors associated with ADRs in 
chronic disease patients of tertiary care teaching hospital. 
Study setting and Design: A Prospective observational longitudinal study was conducted in a tertiary care teaching hospital at Hyderabad, 
India, for 3 years. 
Materials and Methods: Patients of age group > 18 years were included in the study. All the patients were distributed according to their 
gender, age, number medications used, disease condition, and socioeconomic state. The reported ADRs were analyzed by WHO-UMC causality, 
Hartwig’s Siegel’s scale and modified Shumock and Thornton criteria respectively. Statistical analysis used: Descriptive statistical analysis was 
used. 
Results: A total of 691 patients enrolled in the study, in that 391 patients reported with 510 ADRs. Of these 37.0% are in-patients and 62.9% 
are out-patients. Majority of the patients are female category (58.0%) and 45.8% of ADRs reported from adults (41-60 years). 65.8% patients 
are non-adherent to medication. Life style habits, economic status and education are found to be predictors for ADRs. WHO-UMC scale showed 
42.9% of ADRs probable. Hartwig’s and Siegel’s severity scales shown 13.1 % ADRs are severe followed by 33.7% moderate ADRs and 40% of 
ADRs were preventable. 
Conclusion: Hence our study advises that there is a need of improvement in ADR reporting from health care professionals. This study also 
suggests further research in India for the improvement of possible intervention strategies to reduce burden and cost of ADR.  
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INTRODUCTION 
According to WHO Pharmacovigilance (PV) is defined as the 
science and activities relating to the detection assessment, 
understanding and prevention of adverse effects or any 
other drug-related problem. WHO established its 
Programme for International Drug Monitoring in response 
to the thalidomide disaster detected in 1962.1  The objective 
of PvPI is, to monitor ADRs in Indian population, to create 
awareness amongst health care professionals about the 
importance of ADR reporting in India, to monitor benefit-
risk profile of medicines, generate independent, evidence 
based recommendations on the safety of medicines, support 
the CDSCO for formulating safety related regulatory 
decisions for medicines, communicate findings with all key 
stake holders and create a national centre of excellence as 
par with global drug safety monitoring standards.2  
It is generally recommended to treat each chronic condition 
in accordance with disease-specific guidelines. However, 
most clinical practice guidelines do not modify or discuss the 
applicability of their recommendations for older patients 
with multiple diseases and following all guidelines for each 
and every drug a patient is taking will inevitably lead to 
polypharmacy.3According to estimates, India has the highest 
number of adults with diabetes reported at 50.8 millions in 
2010 which is expected to rise to 87 million by 2030.4 The 
prevalence of diabetes has been reported to be rapidly 
increasing in both rural and urban India.5 Prescriber’s 
knowledge about pharmacokinetics and pharmacodynamic 
aspects of medicines and their interaction with normal aging 
physiology is critical in the management of diabetes mellitus. 
The knowledge is needed to minimize and even avoid the 
potentially adverse effects of hypoglycemia and side effects 
associated with the anti-diabetic drugs.6  
In the year 2000, it was also found that the world was 
estimated to have 1 billion people with hypertension and 
predicted to increase to 1.56 billion by 2025.7  
Antihypertensive medications are frequently associated with 
Adverse Drug Reactions which may limit treatment options 
and reduce patient compliance, which may hinder Blood 
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Pressure control. It was believed that different 
discontinuation rates for various classes of antihypertensive 
medications are probably related to their different rates of 
adverse symptoms.8, 9 Treatment of TB requires the use of 
expensive and toxic anti-tubercular drugs which are given 
for a longer duration.10, 11 The Revised National Tuberculosis 
Control Program (RNTCP) in India follows the 
internationally recommended directly observed treatments 
(DOTS) guidelines for treatment TB from August 2007 
onward.12  
 The female gender, age (very young and very old), multiple 
medications and the co-morbid medical conditions, 
socioeconomic status, educational status and lifestyle habits 
are considered as the important risk factors for ADRs.13 
People with diabetes have an increased risk of developing a 
number of serious health problems. Consistently high blood 
glucose levels can lead to serious diseases affecting the heart 
and blood vessels, eyes, kidneys, nerves and teeth. In 
addition, people with diabetes also have a higher risk of 
developing infections.14 Globally 70% of diabetic patients are 
reported to be affected with hypertension and the risk of 
development of hypertension is twice for diabetic patients as 
compared to euglycemic subjects.15 A high prevalence of 
DRPs has been observed in T2DM patients.16 
MATERIALS AND METHODS 
Present study was carried out in Bhaskar Medical College 
and General Hospital, a tertiary care teaching hospital 
located in Hyderabad. The study assessed the causality, 
severity and preventability of ADRs in chronic diseases. Also, 
the study determined the prevalence of ADRs associated 
with their educational status, medication adherence, 
occupation and socioeconomic factors of patients. 
Our institute is the recognized ADR monitoring center (AMC) 
under the “pharmacovigilance program of India.” The AMC 
collects suspected ADR reports from physicians, clinical 
pharmacy interns, PG medical students as well as nearby 
teaching hospitals. We transmit reports to the “VigiFlow 
software “of the WHO for the global monitoring of ADRs 
provided by Indian Pharmacopoeia Commission, Ghaziabad, 
India. 
Study Design 
Prospective observational longitudinal study with active 
pharmacovigilance reporting system. 
Study Period 
The study was conducted over a period of 3 years from May 
2015 to April 2018. 
Ethics committee approval 
The study protocol was reviewed and approved by 
Institutional Human Ethical Committee of Bhaskar Medical 
College and General Hospital authority prior to the 
commencement of study.  
Study criteria 
Inclusion Criteria 
 Patients of age from 18 years and both genders 
 Both inpatients and outpatient 
 Patients with any chronic disease and co-morbid 
medical condition 
Exclusion Criteria 
 Children’s and pregnant women.  
 Patients receiving medicines other than allopathic  
 Patients who experienced adverse event to vaccines, 
blood and /or blood products. 
 Adverse event to poisoning/ drug abuse and 
dependence 
Source of Data 
Patient case sheets including clinicians’ admission notes, 
previous discharge summaries available with the patient, 
reference note from other clinicians and discussion with the 
patient or their care takers at the time of patients’ inclusion 
were considered as sources of past medical and medication 
history for both inpatients and outpatients. Clinicians’ notes, 
discussion with the Interns/ medical postgraduate (PG) 
students were the important sources of information for 
current medical conditions. Daily medication use during 
hospital stay was reviewed from nursing notes. Outpatient’s 
drug usage was confirmed from OPD cards, prescription and 
pharmacy bills or the empty strip of the medication carried 
by the patient or the care taker.  
Assessment of ADR reports 
Organ Systems Affected due to ADRs 
International Statistical Classification of Diseases and 
Related Health Problems 10th Revision. 
Medications Implicated in ADRs 
Drugs that implicated in adverse reaction were coded using 
the WHO Anatomical, 
Therapeutic and Chemical (ATC) classification 
Statistical Analysis  
Descriptive statistics were used for data analysis. All values 
were expressed in percentages and depicted using tables 
and charts. Data were subdivided based on age, gender, 
number of drugs used, drugs class, medication adherence, 
habits, economic status, education and occupation.  
RESULTS & DISCUSSION 
1. Study Population 
691 patients met the study criteria were included in the 
study. Of which 37.0% (n=256) were inpatients and 62.9% 
(n=435) were outpatients. 
2. Characteristics of the Study Population 
Out of 691 study patients, 41.9% (n=290) and 58.0% 
(n=401) were male and female respectively. Majority of the 
patients were in the age group of 40 – 60 (45.8%). 46% of 
patients using drugs between 1-2 drugs. 65.8% of patients 
are non adherent to their medication. 34.5% of patients are 
both alcoholic and smokers. 50.6% patients are not 
educated. 25.4% of patients are unemployed followed by 
20.1% patients are formers and 34% of patients are 
economically lower in class. The demographic details of the 
study population are given in Table 1. 
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Table 1 Demographic details of the study population 
Characteristics 
Inpatients (%) 
(n=256) 
Outpatients (%) 
(n=435) 
Total (%) 
(n=691) 
Gender Male 107 (41.7)  183 (42.0) 290 (41.9)  
Female 149 (58.2) 252 (57.9)  401 (58.0) 
Age Young Adult (19-39) 45 (17.5) 44 (10.1) 89 (12.8) 
Adult (40-60) 112 (43.7) 205 (47.1) 317 (45.8) 
Elderly (> 61) 99 (38.6) 186 (42.7) 285 (41.2) 
No. of Drugs 1 – 2  116 (45.3) 202(46.4) 318 (46.0) 
3 – 4  89 (34.7) 169 (38.8) 258 (37.3) 
≥5 51 (19.9) 64 (14.7) 115 (16.6) 
Medication 
adherence 
Adherence 89 (34.7) 147 (33.7) 236 (34.1) 
Non 167 (65.2) 288 (66.2) 455 (65.8) 
Social habits 
 
Nil 39 (15.2) 80 (18.3) 119 (17.2) 
Alcoholic 57 (22.2) 110 (25.2) 167 (24.1) 
Smoker 59 (23.0) 93 (21.3) 152 (21.9) 
Alcoholic& Smoker 99 (38.6) 140 (32.1) 239 (34.5) 
Abuse  02 (0.7) 12 (2.7) 14 (2.0) 
Education 
 
Illiterate 141(55.0) 209 (48.0) 350 (50.6) 
Primary edu 66 (25.7) 102 (23.4) 168 (24.3) 
Secondary 32 (12.5) 75 (17.2) 107 (15.4) 
Pre university 13 (5.0) 34 (7.8) 47 (6.8) 
university 04 (1.5) 15 (3.4) 19 (2.7) 
Occupation 
 
Student 17 (6.6) 22 (5.0) 39 (5.6) 
Daily worker 55 (21.4) 87 (20.0) 142 (20.5) 
Homemaker 32 (12.5) 85 (19.5) 117 (16.9) 
Agriculture 62 (24.2) 77 (3.9) 139 (20.1) 
Salaried/ Busin 29 (11.3) 49 (11.2) 78 (11.2) 
Unemployed 61 (23.8) 115 (26.4) 176 (25.4) 
Socioeconomic 
 
Upper 03 (1.1) 18 (4.1) 21 (3.0) 
Upper middle 12 (4.6) 54 (12.4) 66 (9.5) 
Middle Class 51(19.9) 98 (22.5) 149 (21.5) 
Lower Middle  91 (35.5) 129 (29.6) 220 (31.8) 
Lower Class 99 (38.6) 136 1.2) 235 (34.0) 
 
a. Classification of disease condition according to ICD-10 Version: 2016 
Out of 691 patients 41.6% patients having endocrine, nutritional and metabolic diseases (E00-E90), followed by 18.6% certain 
infectious and parasitic diseases (A00-B99). The disease condition details are given in Table 2 
Table 2 Classification of disease condition according to ICD-10 
ICD10 
Chapter 
Disease Condition ICD-10 
Code 
Total 
(n=691) 
Incidence 
(%) 
I Certain infectious and parasitic diseases (A00-B99) 129 18.6 
II Neoplasams (C00-D48) 1 0.1 
III Diseases of the blood and blood-forming organs and certain 
disorders involving the immune mechanism 
(D50-D89) 18 2.6 
IV Endocrine, nutritional and metabolic diseases (E00-E90) 288 41.6 
V Mental and behavioural disorders (F00-F99) 7 1.0 
VI Diseases of the nervous system (G00-G99) 29 4.1 
VII Diseases of the eye and adnexa (H00-H59) 2 0.2 
VIII Diseases of the ear and mastoid process (H60-H95) 2 0.2 
IX Diseases of the circulatory system (I00-I99) 44 6.3 
X Diseases of the respiratory system (J00-J99) 22 3.1 
XI Diseases of the digestive system (K00-K93) 23 3.3 
XIII Diseases of the musculoskeletal system and connective tissue (M00-M99) 18 2.6 
XIV Diseases of the genitourinary system (N00-N99) 10 1.4 
XV Pregnancy, childbirth and the puerperium (O00-O99) 15 2.1 
XVIII Symptoms, signs and abnormal clinical and laboratory findings, not 
elsewhere classified 
(R00-R99) 75 10.8 
Chapter XIX Injury, poisoning and certain other consequences of external causes (S00-T98) 1 0.1 
Chapter XXI Factors influencing health status and contact with health services (Z00-Z99) 7 1.0 
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3. Medication Non-Adherence 
Out of 691 patients 455 (65.8%) are non-adherent to their 
medication to due to following factors. In that 39.3% of 
patients are not following their medications due to drug 
related factors. The details of medication non-adherence are 
given in Table 3 
Table 3. The reasons for medication non- adherence 
Factors affecting Medication 
adherence 
Number (%)   
(n=455) 
Drug Related Factors 179  (39.3) 
Patient Related Factors 128 (28.1) 
Disease Related Factors 97 (21.3) 
Health System Related Factors 51 (11.2) 
 
 
4. Adverse Drug Reaction 
Out of 691 patients enrolled in the study 391 patients reported with 510 ADRs during the study period. The incidence of ADRs 
details are given in Table 4 
Table 4. Incidence of ADRs based on patient characteristics 
Characteristics Number 
of patients 
(n=691) 
Number of 
patients with 
ADR (n=391) 
Incidence Number 
of ADRs 
(n=510) 
Percentage 
of ADRs(%) 
Category 
Inpatients 256 106 41.4 143 28.0 
Out patients 435 285 65.5 367 71.9 
Gender 
Male 290 190 65.5 239 46.8 
Female 401 201 50.1 271 53.1 
Age ( years) 
Young Adults 89 31 34.8 48 9.4 
Adults 317 187 58.9 258 50.5 
Elderly (> 61) 285 173 60.7 204 40.0 
Number of Medications 
1-2 318 218 68.5 261 51.1 
3-4 258 108 41.8 159 31.1 
>5 115 65 56.5 90 17.6 
Medication Adherence 
Adherence 236 113 47.8 169 33.1 
Non Adherence 455 278 61.0 341 66.8 
Disease condition ICD-10 
(A00-B99) 129 107 82.9 176 34.5 
(C00-D48) 1 1 100 1 0.1 
(D50-D89) 18 9 50 13 2.5 
(E00-E90) 288 145 50.3 152 29.8 
(F00-F99) 7 4 57.1 6 1.1 
(G00-G99) 29 17 58.6 24 4.7 
(H00-H59) 2 1 50 1 0.1 
(H60-H95) 2 1 50 1 0.1 
(I00-I99) 44 23 52.2 26 5.0 
(J00-J99) 22 16 72.7 21 4.1 
(K00-K93) 23 11 47.8 13 2.5 
(M00-M99) 18 6 33.3 9 1.7 
(N00-N99) 10 4 40 7 1.3 
(O00-O99) 15 8 53.3 12 2.3 
(R00-R99) 75 34 45.3 42 8.2 
(S00-T98) 1 1 100 1 0.1 
(Z00-Z99) 7 3 42.8 5 0.9 
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a. Department-wise distribution of ADRs 
Maximum number of ADRs were reported from the 
department of general medicine (69.5%),similar with the 
study done by Rajeshreddy SGSV et al.17  followed by 
Pulmonology (15.8%), OBG (5.8%) and DVL (2.5%). The 
department wise details are given in Table 5
 
Table 5. Department wise distribution of ADRs 
Department No. of ADRS  (n=510) Incidence (%) 
General Medicine 356  69.8 
Pulmonology 78 15.2 
Obstetrics and gynaecology 30 5.8 
DVL ( dermatology, vernerology, leprology) 16 3.1 
Orthopaedics  9 1.7 
Psychiatry  9 1.7 
Other* 12 2.3 
(* casualty, ENT, neurology & surgery) 
b. Anatomical and Therapeutic Class of medication 
implicated in ADRs 
Drugs acting on alimentary tract and metabolism accounts 
for 34.5% and anti-infective for systemic use reports 33.3% 
ADRs having similar reports from the study done by Patel, et 
al.18 are the most common anatomical class of medication 
implicated in ADRs. The details of Anatomical and 
Therapeutic Class of medication implicated in ADRs are 
given in Table 6 
 
Table 6. Anatomical and Therapeutic Class of medication implicated in ADRs 
Anatomical class [Code] 
(Number of ADRs) 
Therapeutical class [Code] Number of 
ADRs  
n= 510(%) 
Alimentary tract and metabolism [A] 
[n=176 (34.5)] 
 
Drugs for acid related disorders [A02] 29 
Antiemetics and Antinauseants [A04] 23 
Drugs used in diabetes [A10] 90 
Vitamins [A11] 34 
Blood  and blood forming organs [B] 
[n=5 (0.9)] Antithrombotic Agents [B01] 
5 
Cardiovascular system [C] 
[n=34 (6.6)] 
Antihypertensive [C02] 16 
Diuretics [C03] 5 
Beta blocking agents [C07] 3 
Calcium Channel Blockers [C08] 4 
lipid modifying agents [C10] 6 
Systemic hormonal preparations,  
excl. sex hormones and insulins [H] 
[n=31 (6.0)] 
 
Corticosteroids for systemic use [H02] 27 
 Thyroid therapy [H03] 
4 
Anti-infective for systemic use [J] 
[n=170 (33.3)] 
 
 Antimycobacterial [J04]   118 
Antibacterials for systemic use [J01 ] 48 
Antivirals For Systemic use [J05 ] 
4 
Musculo-Skeletal system [M] 
[n=19 (3.7)] Antiinflammatory  [M01] 
19 
Nervous system [N] 
[n=55 (10.7)] 
 
Analgesic [N02] 30 
Antiepileptics [N03] 17 
Psycholeptics [N05 ] 4 
Other nervous system drugs [N07] 2 
Antidepressants [N06a ] 
2 
Antiparasitic products,  
insecticides and repellents [P] 
[n=11 (2.1)] 
 
Ectoparasiticides, incl. Scabicides, insecticides 
and repellents [P03] 
2 
Antiprotozoals [P01] 
9 
Respiratory System [R] 
[n=9 (1.7)] Drugs for obstructive airway diseases [R03] 
9 
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c. Organ system affected by ADRs. 
In our study gastrointestinal system accounts for 26.2% 
ADRs and Skin disorders accounts for 26%, having similar 
reports from the study done by R.J. Lihite et al. and Rehan HS 
et al.19, 20 The details of   organ system affected are given in 
Table 7. 
 
Table 7. Distribution of ADRs based on system organ class affected 
System organ class (WHOART SOC code) Number of 
ADRs (n=510) 
Incidence (%) 
Body as a whole - general disorders (1810) 59 11.5 
Cardiovascular disorders (1010) 7 1.3 
Central & peripheral nervous system disorders 0410 44 8.6 
Gastro-intestinal system disorders (0600) 134 26.2 
Hearing and vestibular disorders 0432 01 0.1 
Heart rate and rhythm disorders 1030 4 0.7 
Liver and biliary system disorders 10 1.9 
Metabolic and nutritional disorders 0800 62 12.1 
Musculo-skeletal system disorders 0200 12 2.3 
Platelet, bleeding & clotting disorders 1230 07 1.3 
Psychiatric disorders 0500 12 2.3 
Red blood cell disorders (1210) 04 0.7 
Respiratory system disorders 1100 09 1.7 
Skin and appendages disorders (0100) 133 26.0 
Urinary system disorders 1300 08 1.5 
Special senses other, disorders 0433 01 0.1 
Vision disorders 0431 01 0.1 
White cell disorders 1220 02 0.3 
 
d. Types of medication implicated in ADRs 
Antimicrobial agents accounts for 35.4% (n=181), which is in 
accordance with the result of studies done by Murphy B et. al 
and Lukshmy M Hettihewa et al.21, 22 and antidiabetic drugs 
accounts for 17.6% (n=90) followed by analgesic and anti-
inflammatory drugs (9.6%, n= 49) of ADRs. The details of 
types of medication are given in Figure 2. 
 
 
Figure 2: Type of medication implicated in ADRs 
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e. Type of Reporters 
All the ADRs reported spontaneously, in that majority of the 
ADRs (28.8%) were reported by PG/ Pharm.D Interns, 
followed by physicians (22.7) and nurses (18.8%). Highest 
reporting from Pharm.D interns, because active participation 
in daily ward rounds and performing bedside patient 
counselling and patient to patient interaction. Surprisingly 
patients are also involved in reporting of the ADRs showing 
that improvement in awareness of drug usage and related 
problems. The details of reporters are given in Figure 3
. 
 
Figure 3. Type of reporters 
f. Predictability of the ADRs 
A total of 76.6% (n=391) of the adverse drug reactions were 
predictable, related with the study Asawari L Raut et al.23 
and 23.3% (n= 119) of the adverse drug reactions were not 
predictable. The details of predictability of the ADRs are 
given in Figure 4 
 
 
  Figure 4. Predictability of the ADRs 
 
Approximately three-fourth of reported ADRs was 
predictable. This result perhaps may due to the reason that 
majority of the reactions were exacerbation of 
pharmacological actions of the drugs that act on various 
organs and associated receptor site. 
g. Causality assessment of reported ADRs 
Majority of the ADRs belonged to ‘probable’ in their casual 
relationship, as assessed 
by WHO probability Scale [n=219 (42.9%)], similar with 
study done by Rajeshreddy SGSV et al.17 The causality 
categories of reported ADRs are presented in Figure . 
 
 
Figure 5. WHO-UMC Causality categories of reported 
ADRs 
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The WHO UMC proposed causality assessment is generally 
accepted method and most widely used method for causality 
assessment in clinical practice as they offered a simple 
methodology. Majority of the ADRs were assigned ‘Probable’ 
casual association between the adverse drug event and 
suspected drug. 
h. Severity assessment of ADRs 
Most of the reported ADRs were of ‘Mild’ in their severity 
and hence did not require withdrawal of the suspected drug 
especially when the benefits outweighed the risk. This 
finding coincide with ponnusankar et al., Dindayal Patidar et 
al.  24, 25 the details of severity of ADRs are given in Figure 6. 
 
                    Figure 6. Severity of ADRs 
i. Preventability of the ADRs 
Of the 510 reported ADRs, 269 (52.7%) were classified as 
probable preventable, which is variance with the study done 
by ponnusankar et al.24 The details of the preventability of 
ADRs are presented in Figure 7. 
Figure 7. Preventability of ADRs 
 
 
CONCLUSION 
Our findings suggest students’ reports were valuable and 
offered clinically relevant information. ADR monitoring 
through spontaneous reporting system helps to ensure 
patient safety through detection of new, serious, and rare 
drug reactions. Pharm.D interns and PG medical students as 
a future health‑care professional should be exposed to ADR 
reporting during their clinical teaching posting. The present 
study relates to ADR profile of tubercular agents, 
antidiabetic drugs, cardiovascular and antibiotics, it is 
important to notice the physicians with latest adverse drug 
reactions of most commonly prescribed medicines in 
hospitals. Hence effective implementation of 
pharmacovigilance would result in better strict vigilance use 
of these drugs and their safety assessment which would 
ultimately result in better patient care. 
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